Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
- Platzbecker, U
- Avvisati, G
- Cicconi, L
- Thiede, C
- Paoloni, F
- Vignetti, M
- Ferrara, F
- Divona, M
- Albano, F
- Efficace, F
- Fazi, P
- Sborgia, M
- Di Bona, E
- Breccia, M
- Borlenghi, E
- Cairoli, R
- Rambaldi, A
- Melillo, L
- La Nasa, G
- Fiedler, W
- Brossart, P
- Hertenstein, B
- Salih, Hr
- Wattad, M
- Lübbert, M
- Brandts, Ch
- Hänel, M
- Röllig, C
- Schmitz, N
- Link, H
- Frairia, C
- Pogliani, Em
- Fozza, C
- D'Arco, Am
- Di Renzo, N
- Cortelezzi, A
- Fabbiano, F
- Döhner, K
- Ganser, A
- Döhner, H
- AMADORI, SERGIO
- Mandelli, F
- Ehninger, G
- Schlenk, Rf
- LO COCO, FRANCESCO
Publication date
January 2017
DOIAbstract
The initial results of the APL0406 trial showed that the combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the final analysis on the complete series of patients enrolled onto this trial
Add to ORKG